拉米夫定联合重组人干扰素α―2b治疗慢性乙型病毒性肝炎的临床疗效.docVIP

拉米夫定联合重组人干扰素a -2b治疗慢性乙型病毒性肝炎的临床疗效 ［ ］H的探讨拉米夫定联合重组人干扰素a-2b治疗慢性乙型 病毒性肝炎的临床疗效。方法选择2014年1?12月在我院治疗的慢 性乙型病毒性肝炎患者60例为研究对象，随机分为研究组和对照组各 30例。两组均给予拉米夫定治疗，研究组在此基础上给予重组人干扰 素0-213治疗。比较两组治疗后41^恢复正常率、邢￥-1）似转阴率、1^^8 转阴率、HBeAg转化率、总右效率以及不良反应情况。结果治疗后， 研究组ALT恢复正常率、HBV-DNA转阴率、HBeAg转阴率、HBeAg转化 率均显著高于对照组，差异有统计学意义（P〈0.05）。研究组总有效率 显著高于对照组，差异有统计学意义（P〈0.05）。两组不良反应比较差 异无统计学意义（P〉0. 05）。结论拉米联合夫定重组人干扰素a-2b 治疗慢性乙型病毒性肝炎能够显著提高临床疗效，并且未明显增加不 良反应，值得临床推广。 ，供学习和研宄 使用， 和著作权归原 所有， 己 如果需耍分享， 请保留本段说明。 ［关键词］拉米夫定；重组人干扰素a-2b;慢性乙型病毒性肝炎; 免疫调节；抗纤维化 ［ ］R978.7 ［ ］B ［ ］1673-9701 (2017) 03-0089-03 Clinical efficacy of lamivudine combined with recombinant human interferon a 一2b in the treatment of chronic hepatitis B virus ZHU Hongxin Shenyang Sixth People’s Hospital, Shenyang 110006， China ［Abstract］ Objective To investigate the clinical efficacy of lamivudine combined with recombinant human interferon a -2b in the treatment of chronic hepatitis B virus. Methods Sixty patients with chronic hepatitis B virus treated in our hospital from January to December 2014 were randomly divided into study group and control group, with 30 cases in each group. Two groups were all given lamivudine treatment, and the study group was also given recombinant human interferon a -2b. ALT normalization rate， HBV-DNA negative rate， HBeAg negative rate, HBeAg conversion rate, total effective rate and adverse reactions between the two groups after the treatment were compared. Results After treatment, ALT normalization rate, HBV-DNA negative rate， HBeAg negative rate, HBeAg conversion rate were significantly higher than those of the control group, and the difference between the two groups was statistically significant(P0. 05). The total effective rate of the study group was significantly higher than that of the control group, and the difference was statistically significant (P〈0.05) . There was no significant difference in adverse reactions between the two groups (P0. 05) . Conclusion The combination of lamivudine and recombinant human in